The role of vasoactive intestinal peptide in pulmonary diseases.

[1]  E. Liu,et al.  C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus , 2022, Microbiology spectrum.

[2]  J. Leuppi,et al.  Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial , 2022, Trials.

[3]  J. Javitt,et al.  The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial* , 2022, Critical care medicine.

[4]  S. Athari,et al.  Immunomodulatory effect of N‐acetyl‐seryl‐aspartyl‐proline and vasoactive intestinal peptide on chronic obstructive pulmonary disease pathophysiology , 2022, Fundamental & clinical pharmacology.

[5]  B. Cockrill,et al.  Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. , 2022, JAMA.

[6]  M. Konstan,et al.  What Is Cystic Fibrosis? , 2022, JAMA.

[7]  T. Behl,et al.  Anticipated pharmacological role of Aviptadil on COVID-19 , 2021, Environmental Science and Pollution Research.

[8]  F. Zhou,et al.  The Role of Vasoactive Intestinal Peptide and Mast Cells in the Regulatory Effect of Lactobacillus casei ATCC 393 on Intestinal Mucosal Immune Barrier , 2021, Frontiers in Immunology.

[9]  J. Duan,et al.  Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells. , 2021, International immunopharmacology.

[10]  A. G. D’amico,et al.  Modulatory role of PACAP and VIP on HIFs expression in lung adenocarcinoma , 2021, Peptides.

[11]  L. Sequist,et al.  Lung cancer , 2021, The Lancet.

[12]  J. Davies,et al.  Cystic fibrosis , 2021, The Lancet.

[13]  F. Zhang,et al.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms , 2020, Pharmacological Research.

[14]  Carolina Q. Sacramento,et al.  VIP plasma levels associate with survival in severe COVID‐19 patients, correlating with protective effects in SARS‐CoV‐2‐infected cells , 2020, bioRxiv.

[15]  R. Croll,et al.  Disrupted local innervation results in less VIP expression in CF mice tissues. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  D. von Bubnoff,et al.  Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis. , 2020, The New England journal of medicine.

[17]  R. Zolty.  Pulmonary arterial hypertension specific therapy: The old and the new. , 2020, Pharmacology & therapeutics.

[18]  L. Hoffman,et al.  Lung function and microbiota diversity in cystic fibrosis , 2020, Microbiome.

[19]  Heng Li,et al.  Coronavirus disease 2019 (COVID-19): current status and future perspectives , 2020, International Journal of Antimicrobial Agents.

[20]  Gang Li,et al.  Vasoactive intestinal peptide stimulates bone marrow-mesenchymal stem cells osteogenesis differentiation by activating Wnt/β-catenin signaling pathway and promotes rat skull defect repair. , 2020, Stem cells and development.

[21]  M. Kohanski,et al.  Neuropeptide regulation of secretion and inflammation in human airway gland serous cells , 2020, European Respiratory Journal.

[22]  Chen-Yu Zhang,et al.  Vasoactive intestinal peptide suppresses the NLRP3 inflammasome activation in lipopolysaccharide-induced acute lung injury mice and macrophages. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  R. Ramhorst,et al.  Vasoactive Intestinal Peptide induces glucose and neutral amino acid uptake through mTOR signalling in human cytotrophoblast cells , 2019, Scientific Reports.

[24]  C. Murray,et al.  Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The Lancet.

[25]  W. Travis,et al.  Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement , 2019, American journal of respiratory and critical care medicine.

[26]  Asmahan Abu-Arish,et al.  Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains , 2019, The Journal of general physiology.

[27]  M. Karolczak-Bayatti,et al.  Vasoactive intestinal peptide shapes first‐trimester placenta trophoblast, vascular, and immune cell cooperation , 2019, British journal of pharmacology.

[28]  Kotaro Sakamoto,et al.  Discovery of artificial VIPR2-antagonist peptides possessing receptor- and ligand-selectivity. , 2018, Biochemical and biophysical research communications.

[29]  R. Jensen,et al.  Neuropeptide G Protein-Coupled Receptors as Oncotargets , 2018, Front. Endocrinol..

[30]  W. Zhong,et al.  Vasoactive intestinal peptide overexpression mediated by lentivirus attenuates lipopolysaccharide‐induced acute lung injury in mice by inhibiting inflammation , 2018, Molecular immunology.

[31]  Y. Shang,et al.  Vasoactive intestinal peptide inhibits airway smooth muscle cell proliferation in a mouse model of asthma via the ERK1/2 signaling pathway , 2018, Experimental cell research.

[32]  C. Brightling,et al.  Asthma , 2018, The Lancet.

[33]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: pathogenesis and management , 2018, Respiratory Research.

[34]  A. Verma,et al.  Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases. , 2017, Cytokine & growth factor reviews.

[35]  P. Sly,et al.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It? , 2017, American journal of respiratory and critical care medicine.

[36]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis , 2017, The Lancet.

[37]  Sonya J. Hwang,et al.  NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease , 2017, PloS one.

[38]  I. Adcock,et al.  Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice. , 2016, European journal of pharmacology.

[39]  A. Couvineau,et al.  Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47phox phosphorylation pathway in monocytes , 2016, Mucosal Immunology.

[40]  Dao-xin Wang,et al.  Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice , 2016, Scientific Reports.

[41]  R. Jensen,et al.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer , 2016, Current opinion in endocrinology, diabetes, and obesity.

[42]  Scott J. Shandler,et al.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice , 2015, The Journal of Neuroscience.

[43]  A. Torbicki,et al.  Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[44]  R. Jensen,et al.  Neuropeptides as lung cancer growth factors , 2015, Peptides.

[45]  H. Bogaard,et al.  Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. , 2015, Reproductive Toxicology.

[46]  Tian Liu,et al.  Vasoactive intestinal peptide suppresses macrophage‐mediated inflammation by downregulating interleukin‐17A expression via PKA‐ and PKC‐dependent pathways , 2015, International journal of experimental pathology.

[47]  M. Tamm,et al.  Vasoactive Intestinal Peptide for Diagnosing Exacerbation in Chronic Obstructive Pulmonary Disease , 2015, Respiration.

[48]  D. Ganea,et al.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases , 2015, Acta physiologica.

[49]  M. Koga,et al.  Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats. , 2014, Journal of applied physiology.

[50]  Zhaolin Xu,et al.  Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice. , 2014, American journal of physiology. Cell physiology.

[51]  N. Joo,et al.  Mucociliary clearance and submucosal gland secretion in the ex vivo ferret trachea. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[52]  P. Ward,et al.  Critical Role for the NLRP3 Inflammasome during Acute Lung Injury , 2014, The Journal of Immunology.

[53]  A. MacKenzie,et al.  VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models , 2014, Orphanet Journal of Rare Diseases.

[54]  S. Barde,et al.  The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats , 2013, Neuropeptides.

[55]  A. Koller,et al.  Vasoactive Intestinal Peptide Knockout (VIP KO) mouse model of sulfite-sensitive asthma: up-regulation of novel lung carbonyl reductase , 2011, BMC Immunology.

[56]  S. Said,et al.  VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension , 2011, Respiratory research.

[57]  K. Dickman,et al.  17β-estradiol protects the lung against acute injury: possible mediation by vasoactive intestinal polypeptide. , 2011, Endocrinology.

[58]  M. Beghetti,et al.  Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension , 2011, Respiratory research.

[59]  Dongwon Lee,et al.  Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review , 2011, Respiratory research.

[60]  D. Conrad,et al.  VIP-dependent increase in F508del-CFTR membrane localization is mediated by PKCε. , 2011, American journal of physiology. Cell physiology.

[61]  Yong Zhou,et al.  Vasoactive intestinal peptide re-balances TREM-1/TREM-2 ratio in acute lung injury , 2011, Regulatory Peptides.

[62]  S. Misaka,et al.  Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis , 2011, Peptides.

[63]  A. Samarasinghe,et al.  The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice , 2011, Peptides.

[64]  S. Misaka,et al.  Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[65]  M. Cazzola,et al.  Dual bronchodilatory and pulmonary anti‐inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors , 2010, British journal of pharmacology.

[66]  Dan-dan Feng,et al.  Vasoactive intestinal peptide induces surfactant protein A expression in ATII cells through activation of PKC/c-Fos pathway , 2010, Peptides.

[67]  W. Mosgoeller,et al.  Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients , 2010, Peptides.

[68]  S. Said,et al.  Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? , 2010, European Respiratory Journal.

[69]  S. Misaka,et al.  Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: Anti-inflammatory effect in experimental asthmatic rats , 2010, Peptides.

[70]  P. Kadowitz,et al.  Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation , 2009, Peptides.

[71]  R. Naeije,et al.  Expression of Vasoactive Intestinal Peptide and Related Receptors in Overcirculation-Induced Pulmonary Hypertension in Piglets , 2009, Pediatric Research.

[72]  S. N. Murthy,et al.  Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation , 2009, Peptides.

[73]  C. Guan,et al.  Role of CREB in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells , 2009, Regulatory Peptides.

[74]  S. Said.  The Vasoactive Intestinal Peptide Gene Is a Key Modulator of Pulmonary Vascular Remodeling and Inflammation , 2008, Annals of the New York Academy of Sciences.

[75]  J. Behr,et al.  Inhalation of vasoactive intestinal peptide in pulmonary hypertension , 2008, European Respiratory Journal.

[76]  S. Misaka,et al.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[77]  S. Ballard,et al.  Fluid secretion by submucosal glands of the tracheobronchial airways , 2007, Respiratory Physiology & Neurobiology.

[78]  Jae Young Choi,et al.  Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis. , 2007, The Journal of clinical investigation.

[79]  S. Onoue,et al.  Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD , 2007, Peptides.

[80]  C. Guan,et al.  Intracellular signaling molecules involved in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells , 2007, Peptides.

[81]  W. Seeger,et al.  Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy , 2007, Circulation.

[82]  T. Moody,et al.  Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. , 2007, Current pharmaceutical design.

[83]  J. Waschek,et al.  Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene , 2007, Circulation.

[84]  C. Pan,et al.  Engineering Novel VPAC2-Selective Agonists with Improved Stability and Glucose-Lowering Activity in Vivo , 2007, Journal of Pharmacology and Experimental Therapeutics.

[85]  Zi-qiang Luo,et al.  Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells , 2006, Peptides.

[86]  J. Waschek,et al.  Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[87]  S. Onoue,et al.  Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. , 2006, Life sciences.

[88]  Javier Martín,et al.  Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. , 2006, The American journal of pathology.

[89]  K. Rabe,et al.  Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. , 2006, European journal of pharmacology.

[90]  W. Berger.  Paediatric pulmonary drug delivery: considerations in asthma treatment , 2005, Expert opinion on drug delivery.

[91]  R. Jensen,et al.  Development of Simplified Vasoactive Intestinal Peptide Analogs with Receptor Selectivity and Stability for Human Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-Activating Polypeptide Receptors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[92]  J. Wharton,et al.  Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.

[93]  R. Jensen,et al.  VIP Attenuation of the Severity of Experimental Pancreatitis Is Due to VPAC1 Receptor-Mediated Inhibition of Cytokine Production , 2005, Pancreas.

[94]  S. Onoue,et al.  Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke , 2004, Regulatory Peptides.

[95]  Dan-dan Feng,et al.  Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants. , 2004, Acta pharmacologica Sinica.

[96]  P. Boschetto,et al.  Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis , 2004, European Respiratory Journal.

[97]  E. Goetzl,et al.  c-Maf and JunB Mediation of Th2 Differentiation Induced by the Type 2 G Protein-Coupled Receptor (VPAC2) for Vasoactive Intestinal Peptide1 , 2004, The Journal of Immunology.

[98]  S. Onoue,et al.  Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine. , 2004, Life sciences.

[99]  G. Funk,et al.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.

[100]  M. Delgado,et al.  Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. , 2003, Gastroenterology.

[101]  J. Lötvall,et al.  Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma , 2003, Thorax.

[102]  R. Whyte,et al.  Absent Secretion to Vasoactive Intestinal Peptide in Cystic Fibrosis Airway Glands* , 2002, The Journal of Biological Chemistry.

[103]  M. Delgado.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. , 2002, Biochemical and biophysical research communications.

[104]  C. Pan,et al.  A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. , 2002, Diabetes.

[105]  T. Moody,et al.  A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines , 2001, Cancer.

[106]  G. Filippatos,et al.  Regulation of apoptosis by vasoactive peptides. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[107]  K. Rabe,et al.  The effect of the vasoactive intestinal polypeptide agonist Ro 25–1553 on induced tone in isolated human airways and pulmonary artery , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[108]  R. Jensen,et al.  GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity , 2001, Peptides.

[109]  D. Groneberg,et al.  Expression and Distribution of Vasoactive Intestinal Polypeptide Receptor VPAC2 mRNA in Human Airways , 2001, Laboratory Investigation.

[110]  G. Firestein.  VIP: A very important protein in arthritis , 2001, Nature Medicine.

[111]  T. Moody,et al.  Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. , 2001, Lung cancer.

[112]  T. Moody,et al.  VPAC1 Receptors and Lung Cancer , 2000, Annals of the New York Academy of Sciences.

[113]  C. Martínez,et al.  Receptors and Transcriptional Factors Involved in the Anti‐Inflammatory Activity of VIP and PACAP , 2000, Annals of the New York Academy of Sciences.

[114]  J. Fahrenkrug,et al.  Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template. , 2000, Molecular pharmacology.

[115]  P. Robberecht,et al.  Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor , 2000, Peptides.

[116]  K. Dickman,et al.  Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide , 2000, Regulatory Peptides.

[117]  Annick Thomas,et al.  Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist , 2000, The Journal of Biological Chemistry.

[118]  S. Said,et al.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[119]  E. Muñoz-Elías,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun* , 1998, The Journal of Biological Chemistry.

[120]  P. de Neef,et al.  Influence of selective VIP receptor agonists in the rat gastric fundus. , 1998, European journal of pharmacology.

[121]  P. de Neef,et al.  Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. , 1998, European journal of pharmacology.

[122]  P. Robberecht,et al.  In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor , 1997, Peptides.

[123]  P. Robberecht,et al.  Development of High Affinity Selective VIP1 Receptor Agonists , 1997, Peptides.

[124]  E. Goetzl,et al.  Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. , 1997, The Journal of pharmacology and experimental therapeutics.

[125]  G. Evan,et al.  A License to Kill , 1996, Cell.

[126]  D. Ganea,et al.  Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[127]  I. Rubinstein,et al.  The stable VIP analogue, Ro 24-9981, potentiates bradykinin-induced increases in clearance of macromolecules. , 1995, American Journal of Physiology.

[128]  W. Scheithauer,et al.  Vasoactive intestinal peptide receptor scintigraphy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[129]  I. Gozes,et al.  Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. , 1995, The Journal of pharmacology and experimental therapeutics.

[130]  W. Pryor,et al.  Aqueous extracts of cigarette tar containing the tar free radical cause DNA nicks in mammalian cells. , 1994, Environmental health perspectives.

[131]  W. Scheithauer,et al.  Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. , 1994, The New England journal of medicine.

[132]  R. Garippa,et al.  Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. , 1994, The Journal of pharmacology and experimental therapeutics.

[133]  O. Rorstad,et al.  Comparative study of vascular relaxation and receptor binding by PACAP and VIP , 1993, Peptides.

[134]  T. Moody,et al.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[135]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[136]  S. Said.  Vasoactive intestinal polypeptide and asthma. , 1989, The New England journal of medicine.

[137]  A. Morice,et al.  Vasoactive intestinal peptide as a bronchodilator in severe asthma , 1986, Peptides.

[138]  P. Barnes,et al.  VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. , 1986, Journal of applied physiology.

[139]  L. Diamond,et al.  Relaxation of cat tracheobronchial and pulmonary arterial smooth muscle by vasoactive intestinal peptide: lack of influence by peptidase inhibitors , 1984, British journal of pharmacology.

[140]  A. Morice,et al.  VIP AS BRONCHODILATOR , 1984, The Lancet.

[141]  A. Morice,et al.  VASOACTIVE INTESTINAL PEPTIDE CAUSES BRONCHODILATATION AND PROTECTS AGAINST HISTAMINE-INDUCED BRONCHOCONSTRICTION IN ASTHMATIC SUBJECTS , 1983, The Lancet.

[142]  S. Bloom,et al.  Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. , 1978, Gut.

[143]  M. Grossman,et al.  Intestinal Secretion: Stimulation by Peptides , 1971, Science.

[144]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[145]  K. Yuan,et al.  Inflammation in Pulmonary Arterial Hypertension. , 2021, Advances in experimental medicine and biology.

[146]  Huanxiang Liu,et al.  In silico classification and prediction of VIP derivatives as VPAC1/ VPAC2 receptor agonists/antagonists. , 2015, Combinatorial chemistry & high throughput screening.

[147]  J. Wharton,et al.  Therapeutic targets in pulmonary arterial hypertension. , 2009, Pharmacology & therapeutics.

[148]  T. Lucas,et al.  Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension , 2007, European Journal of Human Genetics.

[149]  S. Said,et al.  Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects , 2004, Cell and Tissue Research.

[150]  R. Henning,et al.  Vasoactive intestinal peptide: cardiovascular effects. , 2001, Cardiovascular research.

[151]  N. Galiè.  Do we need controlled clinical trials in pulmonary arterial hypertension? , 2001, The European respiratory journal.

[152]  D. Bolin,et al.  Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma , 1995, Biopolymers.

[153]  T. Saga,et al.  Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. , 1984, Transactions of the Association of American Physicians.

[154]  I. Lygren,et al.  Radioimmunoassay of vasoactive intestinal polypeptide in plasma. , 1978, Scandinavian journal of gastroenterology.